{"name":"CEBIOTEX","slug":"cebiotex","ticker":"","exchange":"","domain":"","description":"CEBIOTEX is a biotechnology company focused on developing innovative drug delivery systems, particularly in the oncology space. The company's lead product, CEB-01 membrane loaded with SN-38, is currently in Phase 1 clinical trials, while CEB-01 is in Phase 2.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CEB-01","genericName":"CEB-01","slug":"ceb-01","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"CEB-01","genericName":"CEB-01","slug":"ceb-01","phase":"phase_2","mechanism":"CEB-01 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPNjJBXzE5X0pwT3BfalJmLUZ4djRzczM5UEFnWldGSzl6Mkl3Rl81M09wODBaaFBmczNDNkxMWS1Ib05SeV9hUS0zLVZGc05LcnJHYk5OMk9MS3RGVDBKMVR1M1ZhRjdyMVdsbloxYzVnaTJiVlZaaDlfVThseFpSVDRnelUwLVUtUERIVEo5ZUV5b1daclQ2T2d0eFlkWWJaY2dSNWNIcWJsTmdvMDlzdUFacTZ5czczX19CX1dvbS13OV9wZ0lxOHBNWXYtc0RhWXNQNjlBdGpzaGZ4eklUQmNIX3Q3ZXN2ejczZzNlSHo4YWg5aVcyeDBYUjktdlE?oc=5","date":"2025-10-20","type":"pipeline","source":"PR Newswire","summary":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight - PR Newswire","headline":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQM3BKWDI5QWVabl9QYVc4X2hmZTRGMFNvN2V0R2VpMlRZVkFCVDRZejFsWWV2eTZfXzhEMF9yMzVQZmx3akRXTEdLOWV4RjFYdEJfVG1XM2tVWS1CclUwbHNyUEo4TjZBR1JrRE9wYnhDT2xnN3hFZlp4NXRPY1I4UEttUkwyRmly?oc=5","date":"2023-10-27","type":"pipeline","source":"EU-Startups","summary":"101 Top Medical Startups and Companies in Spain (2021) - EU-Startups","headline":"101 Top Medical Startups and Companies in Spain (2021) - EU","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}